English
This article is from The Journal of Clinical Endocrinology and Metabolism , volume 99 . Abstract Context:: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control. Objective:: Our objective was to demonstrate the superiority of pasireotide LAR over octreotide LAR in medically naive patients with acromegaly. Design and Setting:: We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries. Patients:: A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled. Patients either had previous pituitary surgery but no medical treatment or were de novo with a visible pituitary adenoma on magnetic resonance imaging. Interventions:: Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months. At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory
Sign in with your free account to read, download EPUBs or listen.
Ebook · Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study. · Colao, A., Bronstein, M. D., Freda, P., Gu, F., Shen, C.-C., Gadelha, M., Fleseriu, M., van der Lely, A. J. · Internet Archive